Abcam, ab221789, Anti-MSI2 antibody [EP1305Y] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MSI2 antibody. Carrier free. Suitable for IHC-P, IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP1305Y,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IHC-P, IP, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Epitope:Based on the immunogen sequence for this antibody, it is not predicted to detect the shorter isoforms of MSI2.

Product details:
ab221789 is the carrier-free version of
ab76148
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4 Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Musashi-2 (MSI2) is a member of the Musashi RNA‐binding protein family also labeled as MSI-2. The protein is approximately 38 kDa in size. It expresses primarily in stem cells and various tumor types including hematopoietic cells and neural tissue. MSI2 plays a role in maintaining stem cell self-renewal and differentiation by regulating mRNA translation through binding to specific target RNAs.
Biological function summary
MSI2 contributes to the regulation of gene expression with a significant impact on cell fate decisions. It acts as part of a post-transcriptional regulatory complex that controls the stability and translation of specific mRNA targets. MSI2 influences pathways involved in stem cell maintenance and differentiation linking it to cellular processes like proliferation and apoptosis. Its activity is important for normal development and the maintenance of undifferentiated cell states.
Pathways
MSI2 has important roles in the Notch and Wnt signaling pathways. These pathways are vital for stem cell maintenance and tissue regeneration. MSI2 regulates components of these pathways interacting with proteins such as beta-catenin in Wnt signaling. This regulation enhances its involvement in controlling cell proliferation and differentiation contributing to signaling processes that determine cellular behavior.
MSI2 is linked to acute myeloid leukemia (AML) and certain types of solid tumors. Overexpression of MSI2 often correlates with poor prognosis in AML where it impacts cancer progression by modulating genes associated with cell growth. Additionally its interaction with oncogenic proteins like BCR-ABL suggests its involvement in cancerogenesis through disease-linked pathways. Research indicates MSI2 as a potential target for therapeutic intervention in such malignancies.